CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen
Loading...
Citations
Web of Science:
Altmetric:
Altmetric::
Download
File Licence
Editors
Date
2011-08-29
Source Title
Journal of Experimental Medicine (JEM)
Journal Title
Journal ISSN
Volume Title
Publisher
ROCKEFELLER UNIV PRESS
Melbourne Authors
Affiliation
Medical Biology (W.E.H.I.)
Microbiology and Immunology
Microbiology and Immunology
Document Type
Journal Article
Subject Code
Citation
Desch, A. N., Randolph, G. J., Murphy, K., Gautier, E. L., Kedl, R. M., Lahoud, M. H., Caminschi, I., Shortman, K., Henson, P. M. & Jakubzick, C. V. (2011). CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. Journal of Experimental Medicine, 208 (9), pp.1789-1797. https://doi.org/10.1084/jem.20110538.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
Cells undergoing programmed cell death (apoptosis) are removed in situ by macrophages and dendritic cells (DCs) through a specialized form of phagocytosis (efferocytosis). In the lung, there are two primary DC subsets with the potential to migrate to the local lymph nodes (LNs) and initiate adaptive immune responses. In this study, we show that only CD103(+) DCs were able to acquire and transport apoptotic cells to the draining LNs and cross present apoptotic cell-associated antigen to CD8 T cells. In contrast, both the CD11b(hi) and the CD103(+) DCs were able to ingest and traffic latex beads or soluble antigen. CD103(+) DCs selectively exhibited high expression of TLR3, and ligation of this receptor led to enhanced in vivo cytotoxic T cell responses to apoptotic cell-associated antigen. The selective role for CD103(+) DCs was confirmed in Batf3(-/-) mice, which lack this DC subtype. Our findings suggest that CD103(+) DCs are the DC subset in the lung that captures and presents apoptotic cell-associated antigen under homeostatic and inflammatory conditions and raise the possibility for more focused immunological targeting to CD8 T cell responses.